Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Oct 2015

Miyazaki Kana

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, and is regarded as a heterogeneous group of lymphomas in terms of morphologic, immunologic, and cytogenetic features. The current standard therapy for DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy, which allows many patients to achieve disease cure. Despite recent progress in improving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BCL2 gene
Share to Genetic Heterogeneity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Prognosis

Share to Sex Characteristics

Share to Signal Transduction

Source

Identifiers

PMID: 26458444
DOI: 10.11406/rinketsu.56.2047

Genes

BCL2
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].PMID 26458444Read ↗

Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Novel therapeutic targets in diffuse large B-cell lymphomaSemantic proximity Read ↗

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.Semantic proximity Read ↗

Diffuse large B-cell lymphoma.Semantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

Double hit lymphoma: from biology to therapeutic implications.Semantic proximity Read ↗

Aggressive B-cell lymphomas—from morphology to molecular pathogenesisSemantic proximity Read ↗

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read ↗

Molecular pathogenesis of diffuse large B-cell lymphoma.Semantic proximity Read ↗

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapySemantic proximity Read ↗

Double-Hit Large B Cell Lymphoma.Semantic proximity Read ↗

Biological heterogeneity in diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.